💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇮🇳 हिन्दी

Faricimab

CHEMBL4297750 Phase 4 अनुमोदित Antibody
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

This bispecific antibody blocks two pathways, VEGF-A and Ang-2, that cause abnormal blood vessel growth and leakage in the eye. It is injected into the eye to treat neovascular age-related macular degeneration and diabetic macular edema.

चिकित्सीय क्षेत्र

एज-रिलेटेड मैक्युलर डिजनरेशन ऑप्थल्मोलॉजी (नेत्र विज्ञान)

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

This bispecific antibody blocks two pathways, VEGF-A and Ang-2, that cause abnormal blood vessel growth and leakage in the eye. It is injected into the eye to treat neovascular age-related macular degeneration and diabetic macular edema.

Yes, Faricimab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297750. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.